Medicare Benefits Schedule - Item 14247

Extracorporeal photopheresis for the treatment of erythrodermic stage III-IVa T4 M0 cutaneous T-cell lymphoma; if

1. the service is provided in the initial six months of treatment; and
2. the service is delivered using an integrated, closed extracorporeal photopheresis system; and
3. the patient is 18 years old or over; and
4. the patient has received prior systemic treatment for this condition and experienced either disease progression or unacceptable toxicity while on this treatment; and
5. the service is provided in combination with the use of Pharmaceutical Benefits Scheme-subsidised methoxsalen; and
6. the service is supervised by a specialist or consultant physician in the speciality of haematology.

 
Applicable once per treatment cycle

Fee: $2,036.95 Benefit: 75% = $1,527.75 85% = $1,938.25

• Previous - Item 14245
• Next - Item 14249